The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events: A Meta-analysis of Randomized Controlled Trials
Abstract
CONTEXT: Ustekinumab and briakinumab, monoclonal antibodies to the shared p40 subunit of interleukin (IL)-12 and IL-23, have shown efficacy in treating chronic plaque psoriasis (CPP). Preliminary reports of major adverse cardiovascular events (MACEs) in psoriasis patients receiving anti-IL-12/23 agents have prompted concern. OBJECTIVE: To evaluate a possible association between biologic therapies for CPP and MACEs via meta-analysis. DATA SOURCES: Randomized controlled trials (RCTs) of anti-IL-12/23 (ustekinumab and briakinumab) agents and anti-tumor necrosis factor α (TNF-α) agents (adalimumab, etanercept, and infliximab) used in treating CPP were reviewed using the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and Ovid MEDLINE from database inception to May 2011. The results of registered nonpublished completed studies were procured through abstract publications or poster presentations. STUDY SELECTION: Randomized, placebo-controlled, double-blind, monotherapy studies (with safety outcome data for MACE) of IL-12/23 antibodies and anti-TNF-α agents in adults. Studies of psoriatic arthritis were excluded. DATA EXTRACTION: Two investigators independently searched data while 6 investigators reviewed the abstracted data. RESULTS: A total of 22 RCTs comprising 10 183 patients met the predefined inclusion criteria. The primary outcome measure was MACE, a composite end point of myocardial infarction, cerebrovascular accident, or cardiovascular death during the placebo-controlled phase of treatment in patients receiving at least 1 dose of study agent or placebo. Absolute risk differences were used as an effect measure. There was no evidence of statistical heterogeneity across the studies using the I(2) statistic (I(2) = 0), allowing for combination of trial results using the Mantel-Haenszel fixed-effects method. During the placebo-controlled phases of the anti-IL-12/23 studies, 10 of 3179 patients receiving anti-IL-12/23 therapies experienced MACEs compared with zero events in 1474 patients receiving placebo (Mantel-Haenszel risk difference, 0.012 events/person-year; 95% confidence interval [CI], -0.001 to 0.026; P =.12). In the anti-TNF-α trials, only 1 of 3858 patients receiving anti-TNF-α agents experienced a MACE compared with 1 of 1812 patients receiving placebo (Mantel-Haenszel risk difference, -0.0005 events/person-year; 95% CI, -0.010 to 0.009; P = .94). CONCLUSIONS: Compared with placebo, there was no significant difference in the rate of MACEs observed in patients receiving anti-IL-12/IL-23 antibodies or anti-TNF-α treatments. This study may have been underpowered to identify a significant difference.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Risk of myocardial infarction in patients with psoriasis
Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006) · JAMA · doi:10.1001/jama.296.14.1735 · Cited by 1,899
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Self-citationEtanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Self-citationTyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069 · cited 1×
“Gottlieb et al,21 2004 Infliximab 197 51 44 (35-53)g 17 (11-24)g 27 (19-45)g 19 (15-27)g Reich et al,22 2005 Infliximab 301 77 42.”
Self-citationReich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Prevalence of cardiovascular risk factors in patients with psoriasis
Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., Troxel, A. B., & Gelfand, J. M. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.08.040 · Cited by 1,010
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., & Gottlieb, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04954-0 · Cited by 890
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Menter, A., Tyring, S. K., Gordon, K., Kimball, A. B., Leonardi, C. L., Langley, R. G., Strober, B. E., Kaul, M., Gu, Y., Okun, M., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.09.010 · Cited by 889
Self-citationSelective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes
Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D., & Sprent, J. (2006) · Science · doi:10.1126/science.1122927 · Cited by 870
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Self-citationRisk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
Krueger, G. G., Langley, R. G., Leonardi, C., Yeilding, N., Guzzo, C., Wang, Y., Dooley, L. T., & Lebwohl, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062382 · Cited by 807
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Papp, K. A., Tyring, S., Lahfa, M., Prinz, J., Griffiths, C. E. M., Nakanishi, A. M., Zitnik, R., van de Kerkhof, P. C. M., & the Etanercept Psoriasis Study Group (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06688.x · Cited by 693
Gottlieb, A. B., Evans, R., Li, S., Dooley, L. T., Guzzo, C. A., Baker, D., Bala, M., Marano, C. W., & Menter, A. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.02.021 · Cited by 581
Self-citationMenter, A., Feldman, S. R., Weinstein, G. D., Papp, K., Evans, R., Guzzo, C., Li, S., Dooley, L. T., Arnold, C., & Gottlieb, A. B. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.07.017 · Cited by 516
Self-citationGordon, K. B., Langley, R. G., Leonardi, C., Toth, D., Menter, M. A., Kang, S., Heffernan, M., Miller, B., Hamlin, R., Lim, L., et al. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.05.027 · Cited by 510
Self-citationThe Th17/Treg imbalance in patients with acute coronary syndrome
Cheng, X., Yu, X., Ding, Y.-J., Fu, Q.-Q., Xie, J.-J., Tang, T.-T., Yao, R., Chen, Y., & Liao, Y.-H. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.01.009 · Cited by 489
A Randomized Trial of Etanercept as Monotherapy for Psoriasis
Gottlieb, A. B. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.12.1627 · Cited by 470
Blockade of Interleukin-17A Results in Reduced Atherosclerosis in Apolipoprotein E–Deficient Mice
Smith, E., Prasad, K.-M. R., Butcher, M., Dobrian, A., Kolls, J. K., Ley, K., & Galkina, E. (2010) · Circulation · doi:10.1161/circulationaha.109.924886 · Cited by 421
Eid, R. E., Rao, D. A., Zhou, J., Lo, S.-F. L., Ranjbaran, H., Gallo, A., Sokol, S. I., Pfau, S., Pober, J. S., & Tellides, G. (2009) · Circulation · doi:10.1161/circulationaha.108.827618 · Cited by 412
Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis
Taleb, S., Romain, M., Ramkhelawon, B., Uyttenhove, C., Pasterkamp, G., Herbin, O., Esposito, B., Perez, N., Yasukawa, H., Van Snick, J., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090545 · Cited by 408
PRODANOWICH, S., MA, F., TAYLOR, J., PEZON, C., FASIHI, T., & KIRSNER, R. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.06.017 · Cited by 384
Finkelman, F. D., Madden, K. B., Morris, S. C., Holmes, J. M., Boiani, N., Katona, I. M., & Maliszewski, C. R. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.3.1235 · Cited by 366
Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
Konstam, M. A., Weir, M. R., Reicin, A., Shapiro, D., Sperling, R. S., Barr, E., & Gertz, B. J. (2001) · Circulation · doi:10.1161/hc4401.100078 · Cited by 352
The Role of Interleukin 12 in the Development of Atherosclerosis in ApoE-Deficient Mice
Lee, T.-S., Yen, H.-C., Pan, C.-C., & Chau, L.-Y. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.734 · Cited by 311
Kimball, A. B. (2008) · Archives of Dermatology · doi:10.1001/archdermatol.2007.63 · Cited by 214
Self-citationHashmi, S., & Zeng, Q. T. (2006) · Coronary Artery Disease · doi:10.1097/01.mca.0000236288.94553.b4 · Cited by 191
The Th17/Treg functional imbalance during atherogenesis in ApoE−/− mice
Xie, J.-J., Wang, J., Tang, T.-T., Chen, J., Gao, X.-L., Yuan, J., Zhou, Z.-H., Liao, M.-Y., Yao, R., Yu, X., et al. (2010) · Cytokine · doi:10.1016/j.cyto.2009.09.007 · Cited by 186
ASAHINA, A., NAKAGAWA, H., ETOH, T., OHTSUKI, M., & THE ADALIMUMAB M04‐688 STUDY GROUP (2010) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2009.00748.x · Cited by 184
Blockade of Interleukin-12 Function by Protein Vaccination Attenuates Atherosclerosis
Hauer, A. D., Uyttenhove, C., de Vos, P., Stroobant, V., Renauld, J. C., van Berkel, T. J. C., van Snick, J., & Kuiper, J. (2005) · Circulation · doi:10.1161/circulationaha.104.533463 · Cited by 182
Cryer, P. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0448-4 · Cited by 161
Lessons from the withdrawal of rofecoxib: ***
Dieppe, P. A., Ebrahim, S. B. J., Martin, R. M., & Jüni, P. (2004) · BMJ · doi:10.1136/bmj.329.7471.867 · Cited by 139
Emerging Role of IL-17 in Atherosclerosis
Chen, S., Crother, T. R., & Arditi, M. (2010) · Journal of Innate Immunity · doi:10.1159/000314626 · Cited by 113
Derry, S., Loke, Y. K., & Aronson, J. K. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-7 · Cited by 112
May, L. T., Neta, R., Moldawer, L. L., Kenney, J. S., Patel, K., & Sehgal, P. B. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.6.3225 · Cited by 108
Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes
Wyss, C. A., Neidhart, M., Altwegg, L., Spanaus, K. S., Yonekawa, K., Wischnewsky, M. B., Corti, R., Kucher, N., Roffi, M., Eberli, F. R., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq084 · Cited by 107
IL-2 In Vivo Activities and Antitumor Efficacy Enhanced by an Anti-IL-2 mAb
Kamimura, D., Sawa, Y., Sato, M., Agung, E., Hirano, T., & Murakami, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.306 · Cited by 68
Wang, M., Zhang, W., Crisostomo, P. R., Markel, T. A., Meldrum, K. K., Fu, X. Y., & Meldrum, D. R. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00125.2007 · Cited by 68
Menter, A., Griffiths, C. E. M., Tebbey, P. W., Horn, E., & Sterry, W. (2010) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2010.03656.x · Cited by 58
Self-citationPhelan, J. D., Orekov, T., & Finkelman, F. D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.44 · Cited by 48
Cited by
Elmets, C. A., Leonardi, C. L., Davis, D. M. R., Gelfand, J. M., Lichten, J., Mehta, N. N., Armstrong, A. W., Connor, C., Cordoro, K. M., Elewski, B. E., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.058 · Cited by 503
Self-citationIL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
Moschen, A. R., Tilg, H., & Raine, T. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0084-8 · Cited by 473
Armstrong, E. J., Harskamp, C. T., & Armstrong, A. W. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000062 · Cited by 470
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?
Engelen, S. E., Robinson, A. J. B., Zurke, Y.-X., & Monaco, C. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00668-4 · Cited by 425
The Inflammatory Response in Psoriasis: a Comprehensive Review
Deng, Y., Chang, C., & Lu, Q. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8535-x · Cited by 416
Metadata
- Authors
- Ryan, C., Leonardi, C. L., Krueger, J. G., Kimball, A. B., Strober, B. E., Gordon, K. B., Langley, R. G., de Lemos, J. A., Daoud, Y., Blankenship, D., Kazi, S., Kaplan, D. H., Friedewald, V. E., & Menter, A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-08-24
- Volume
- 306
- Issue
- 8
- Pages
- 864-71
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2056361036
- Cited by
- 289
- References
- 46
- FWCI
- 13.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.